Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Rhinol Allergy ; 26(1): e15-9, 2012.
Article in English | MEDLINE | ID: mdl-22391070

ABSTRACT

BACKGROUND: The effect of crenotherapy on major mucosal markers of inflammation, TNF alpha, human beta-defensins 2 (hBD-2), and calprotectin, are largely unexplored in pediatric chronic rhinosinusitis (CRS). The aim of this study was to investigate the effects of crenotherapy with sulfate-sodium-chloride water on mucosal markers of inflammation in children with CRS. METHODS: Children with CRS received 15-day crenotherapy consisting of sulfate-sodium-chloride thermal water inhalations by nasal aerosol (15 minutes/day). Concentrations of nasal mucosal markers of inflammation (TNF alpha, hBD-2, and calprotectin) were measured before and after crenotherapy. Presence of specific symptoms (nasal obstruction, nasal discharge, facial pain, sense of smell, and cough), value of symptoms score sino-nasal 5 (SN5), quality of life (QoL) score (1 [worse] to 10 [optimal]) were also assessed. RESULTS: After crenotherapy a significant reduction was observed in TNF alpha (from 0.14 ± 0.02 to 0.08 ± 0.01; p < 0.001), calprotectin (from 2.9 ± 1.0 to 1.9 ± 0.5; p < 9.001), and hBD-2 (from 2.0 ± 0.1 to 0.9 ± 0.6; p < 0.001) concentrations. A significant (p < 0.05) reduction in number of subjects presenting symptoms of nasal obstruction (100% versus 40%), nasal discharge (33% versus 13%), facial pain (30% versus 10%), and sense of smell (60% versus 20%) was observed. A significant improvement of SN5 (from 3.07 ± 0.76 to 2.08 ± 0.42; p < 0.001) was observed after the crenotherapy. QoL also improved after crenotherapy (from 4.2 ± 1.1 to 6.6 ± 1.0; p < 0.001). CONCLUSION: Crenotherapy induced a down-regulation of nasal mucosal inflammatory mediators in children with CRS.


Subject(s)
Balneology , Mineral Waters/administration & dosage , Nasal Mucosa/metabolism , Rhinitis/therapy , Sinusitis/therapy , Child, Preschool , Chronic Disease , Down-Regulation , Female , Humans , Immunomodulation , Inflammation Mediators/metabolism , Leukocyte L1 Antigen Complex/genetics , Leukocyte L1 Antigen Complex/metabolism , Male , Mineral Waters/adverse effects , Nasal Mucosa/drug effects , Nasal Mucosa/immunology , Nasal Mucosa/pathology , Nasal Sprays , Quality of Life , Rhinitis/immunology , Rhinitis/physiopathology , Sinusitis/immunology , Sinusitis/physiopathology , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism , beta-Defensins/genetics , beta-Defensins/metabolism
2.
World J Gastroenterol ; 17(12): 1519-28, 2011 Mar 28.
Article in English | MEDLINE | ID: mdl-21472114

ABSTRACT

The multiple beneficial effects on human health of the short-chain fatty acid butyrate, synthesized from non-absorbed carbohydrate by colonic microbiota, are well documented. At the intestinal level, butyrate plays a regulatory role on the transepithelial fluid transport, ameliorates mucosal inflammation and oxidative status, reinforces the epithelial defense barrier, and modulates visceral sensitivity and intestinal motility. In addition, a growing number of studies have stressed the role of butyrate in the prevention and inhibition of colorectal cancer. At the extraintestinal level, butyrate exerts potentially useful effects on many conditions, including hemoglobinopathies, genetic metabolic diseases, hypercholesterolemia, insulin resistance, and ischemic stroke. The mechanisms of action of butyrate are different; many of these are related to its potent regulatory effects on gene expression. These data suggest a wide spectrum of positive effects exerted by butyrate, with a high potential for a therapeutic use in human medicine.


Subject(s)
Butyrates/therapeutic use , Gastrointestinal Agents/therapeutic use , Intestinal Diseases/drug therapy , Butyrates/adverse effects , Evidence-Based Medicine , Gastrointestinal Agents/adverse effects , Humans , Intestinal Diseases/metabolism , Intestinal Mucosa/metabolism , Intestines/drug effects
3.
Eur J Pharmacol ; 626(2-3): 266-70, 2010 Jan 25.
Article in English | MEDLINE | ID: mdl-19819236

ABSTRACT

Zn(2+) is effective in the treatment of acute diarrhea, but its mechanisms are not completely understood. We previously demonstrated that Zn(2+) inhibits the secretory effect of cyclic adenosine monophosphate but not of cyclic guanosine monophosphate in human enterocytes. The aim of the present study was to investigate whether Zn(2+) inhibits intestinal ion secretion mediated by the Ca(2+) or nitric oxide pathways. To investigate ion transport we evaluated the effect of Zn(2+) (35 microM) on electrical parameters of human intestinal epithelial cell monolayers (Caco2 cells) mounted in Ussing chambers and exposed to ligands that selectively increased intracellular Ca(2+) (carbachol 10(-6)M) or nitric oxide (interferon-gamma 300 UI/ml) concentrations. We also measured intracellular Ca(2+) and nitric oxide concentrations. Zn(2+) significantly reduced ion secretion elicited by carbachol (-87%) or by interferon-gamma (-100%), and inhibited the increase of intracellular Ca(2+) and nitric oxide concentrations. These data indicate that Zn(2+) inhibits ion secretion elicited by Ca(2+) and nitric oxide by directly interacting with the enterocyte. They also suggest that Zn(2+) interferes with three of the four main intracellular pathways of intestinal ion secretion that are involved in acute diarrhea.


Subject(s)
Calcium/metabolism , Enterocytes/drug effects , Enterocytes/metabolism , Ions/metabolism , Nitric Oxide/metabolism , Zinc/pharmacology , Caco-2 Cells , Enterocytes/cytology , Humans , Intracellular Space/drug effects , Intracellular Space/metabolism , Ion Transport/drug effects , Reproducibility of Results , Signal Transduction/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...